Steven Deeks
Internal Medicine · San Francisco, CANPI 1073604666
Payments from drug & device makers
Across 88 payments — averaging $7317.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$410K
- Viiv Healthcare Company$114K
- Merck$90K
- Pfizer$13K
- AbbVie$5K
- Gen-probe, Inc.$5K
- plus $6K from 5 others
What the payments were for
- Consulting fees$39,10074%
- Speaking & faculty fees$7001%
- Grants$1,0002%
- Travel & lodging$11,07621%
- Food & beverage$1,1162%
- Education$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 23 | $410,234 |
| Viiv Healthcare Company | 21 | $114,491 |
| Merck | 3 | $90,278 |
| Pfizer | 6 | $13,269 |
| AbbVie | 8 | $5,106 |
| Gen-probe, Inc. | 1 | $5,000 |
| Eli Lilly | 20 | $3,762 |
| Janssen Scientific Affairs, LLC | 1 | $1,000 |
| National Marrow Donor Program | 2 | $700 |
| Hologic Sales And Service, LLC | 2 | $102 |
| EMD Serono, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$643,964 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 85 | $347,639 |
| TivicayDolutegravir Sodium | 120 | $279,468 |
| DescovyEmtricitabine/Tenofov Alafenam | 111 | $252,767 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 48 | $178,639 |
| JulucaDolutegravir/Rilpivirine | 20 | $71,183 |
| DovatoDolutegravir Sodium/Lamivudine | 18 | $57,988 |
| PifeltroDoravirine | 33 | $53,567 |
| PrezcobixDarunavir/Cobicistat | 20 | $46,942 |
| Darunavir | 23 | $27,809 |
| Isentress HdRaltegravir Potassium | 12 | $21,752 |
| EliquisApixaban | 12 | $8,501 |
| Ritonavir | 40 | $3,771 |
| Atazanavir Sulfate | 11 | $1,101 |
| Gabapentin | 43 | $702 |
| Testosterone Cypionate | 23 | $621 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $410,234 | $600,406196 claims |
| Viiv Healthcare CompanyTivicay, Juluca, Dovato | $114,491 | $408,639158 claims |
| MerckPifeltro, Isentress Hd | $90,278 | $75,31945 claims |
| PfizerEliquis | $13,269 | $8,50112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in San Francisco
- Rahul AggarwalSan Francisco$24M
- Thomas MartinSan Francisco$13.7M
- Peter HuntSan Francisco$9.8M
- Diane HavlirSan Francisco$8.4M
- Sandy WongSan Francisco$6.6M
- Nina ShahSan Francisco$5.4M
- Katy TsaiSan Francisco$3.8M
- Riley BoveSan Francisco$3.6M
- Jacob LalezariSan Francisco$3.3M
- Flavio VincentiSan Francisco$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.